The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...
GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
The FDA has approved Spravato (esketamine) nasal spray for use as monotherapy for patients with treatment-resistant depression.
Oxford Mail on MSN3d
Research into treatment for treatment-resistant depression begins in OxfordUse precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...
Major strides for the company on two fronts – psychedelic therapies and treatment-resistant depression (TRD) – came in the ...
The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
Inquirer on MSN18h
World’s first anti-depression nasal spray receives FDA approvalThe US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...
ADorset A&E doctor and author, Cathy Wield, details her battles with mental health and recovery in her new memoir Unshackled Mind, due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback